瑞丹韋單抗INN:Regdanvimab),以商品名Regkirona出售,是一種用於治療COVID-19的人單克隆抗體[4]該抗體針對SARS-CoV-2刺突蛋白。它是由賽特瑞恩(Celltrion)開發的。[6][7]該藥物通過靜脈輸注(滴注)給藥。[4][8]

瑞丹韋單抗
單克隆抗體
種類完整抗體
目標SARS-CoV-2刺突蛋白
臨床資料
商品名英語Drug nomenclatureRegkirona
其他名稱瑞達韋單抗、瑞丹維單抗、CT-P59
核准狀況
懷孕分級
給藥途徑靜脈注射
ATC碼
法律規範狀態
法律規範
識別資訊
CAS號2444308-95-4
DrugBank
UNII
KEGG

最常見的副作用包括輸液相關反應,包括過敏反應過敏性休克[4]

瑞丹韋單抗於2021年11月在歐盟獲批用於醫療用途。[4][5]

參考資料

編輯
  1. ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 12 May 2022 [13 May 2022]. (原始內容存檔於3 April 2022). 
  2. ^ AusPAR: Regdanvimab. Therapeutic Goods Administration (TGA). 7 December 2021 [4 January 2022]. (原始內容存檔於5 January 2022). 
  3. ^ TGA Provisional Approval of Celltrion Healthcare Australia Pty Ltd COVID-19 treatment, regdanvimab (Regkirona). Therapeutic Goods Administration (TGA) (新聞稿). 6 December 2021 [4 January 2022]. (原始內容存檔於5 January 2022). 
  4. ^ 4.0 4.1 4.2 4.3 4.4 Regkirona EPAR. European Medicines Agency. 10 November 2021 [12 November 2021]. (原始內容存檔於12 November 2021).  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ 5.0 5.1 Regkirona. Union Register of medicinal products. 12 November 2021 [24 April 2022]. (原始內容存檔於24 April 2022). 
  6. ^ Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform (新聞稿). Celltrion. 11 February 2021 [4 March 2021]. (原始內容存檔於19 October 2021) –透過Business Wire. 
  7. ^ Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59 (新聞稿). Celltrion. 13 January 2021 [4 March 2021]. (原始內容存檔於19 October 2021) –透過Business Wire. 
  8. ^ EMA issues advice on use of regdanvimab for treating COVID-19. European Medicines Agency. 26 March 2021 [15 October 2021]. (原始內容存檔於15 November 2021). 

延伸閱讀

編輯

外部連結

編輯
  • Regdanvimab. Drug Information Portal. U.S. National Library of Medicine. [2023-12-19]. (原始內容存檔於2022-11-27).